Merck KGaA
Diatech Pharmacogenetics, Merck KGaA Expand RAS Biomarker Testing Pact in Middle East, Africa
The companies are collaborating to improve access to biomarker testing to inform the use of targeted therapies in colorectal cancer across the region.
Foundation Medicine Companion Dx Test Gets FDA OK for Use with Merck's Tepmetko in Lung Cancer
The blood-based comprehensive genomic profiling test uses next-generation sequencing to analyze 324 genes.
Merck KGaA Updates Clinical Trial Plans for Several Precision Oncology Candidates
The Darmstadt, Germany-based drugmaker outlined its strategy for advancing an ATR inhibitor, a PARP inhibitor, and an antibody-drug conjugate.
Biocartis, Merck KGaA Extend RAS Testing Partnership to Middle East, North Africa
The companies hope to improve access to biomarker testing to direct more personalized treatment for cancer patients in the region.
Nucleai Raises $14M in Funding Round Led by Merck KGaA's M Ventures
The company said it will use the funds to further apply its AI algorithms in the prospective enrollment of patients in clinical trials.